Business Description
Renalytix PLC
ISIN : GB00BYWL4Y04
Description
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.81 | |||||
| Equity-to-Asset | 0.12 | |||||
| Debt-to-Equity | 3.18 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -12.96 | |||||
| Beneish M-Score | 2.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -42.5 | |||||
| 3-Year EPS without NRI Growth Rate | -42.4 | |||||
| 3-Year FCF Growth Rate | -31.3 | |||||
| 3-Year Book Growth Rate | -50.4 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 99.99 | |||||
| 9-Day RSI | 99.26 | |||||
| 14-Day RSI | 95.68 | |||||
| 6-1 Month Momentum % | 15.68 | |||||
| 12-1 Month Momentum % | -63.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.68 | |||||
| Quick Ratio | 0.64 | |||||
| Cash Ratio | 0.49 | |||||
| Days Inventory | 117.12 | |||||
| Days Sales Outstanding | 143.33 | |||||
| Days Payable | 542.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.4 | |||||
| Shareholder Yield % | -47.83 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 7.48 | |||||
| Operating Margin % | -1607.07 | |||||
| Net Margin % | -1764.04 | |||||
| FCF Margin % | -1500.08 | |||||
| ROE % | -597.11 | |||||
| ROA % | -148.26 | |||||
| ROIC % | -227.69 | |||||
| ROC (Joel Greenblatt) % | -2447.74 | |||||
| ROCE % | -280.86 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.14 | |||||
| PB Ratio | 12.14 | |||||
| EV-to-EBIT | -1.09 | |||||
| EV-to-Forward-EBIT | -1.36 | |||||
| EV-to-EBITDA | -1.13 | |||||
| EV-to-Forward-EBITDA | -1.45 | |||||
| EV-to-Revenue | 17.47 | |||||
| EV-to-Forward-Revenue | 1.5 | |||||
| EV-to-FCF | -1.16 | |||||
| Earnings Yield (Greenblatt) % | -91.74 | |||||
| FCF Yield % | -89.45 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers